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Sauter KA, Waddell LA, Lisowski ZM, Young R, Lefevre L,
Davis GM, Clohisey SM, McCulloch M, Magowan E, Mabbott
NA, Summers KM, Hume DA. Macrophage colony-stimulating
factor (CSF1) controls monocyte production and maturation and the
steady-state size of the liver in pigs. Am J Physiol Gastrointest Liver
Physiol 311: G533–G547, 2016. First published July 21, 2016;
doi:10.1152/ajpgi.00116.2016.—Macrophage colony-stimulating fac-
tor (CSF1) is an essential growth and differentiation factor for cells of
the macrophage lineage. To explore the role of CSF1 in steady-state
control of monocyte production and differentiation and tissue repair,
we previously developed a bioactive protein with a longer half-life in
circulation by fusing pig CSF1 with the Fc region of pig IgG1a.
CSF1-Fc administration to pigs expanded progenitor pools in the
marrow and selectively increased monocyte numbers and their ex-
pression of the maturation marker CD163. There was a rapid increase
in the size of the liver, and extensive proliferation of hepatocytes
associated with increased macrophage infiltration. Despite the large
influx of macrophages, there was no evidence of liver injury and no
increase in circulating liver enzymes. Microarray expression profiling
of livers identified increased expression of macrophage markers, i.e.,
cytokines such as TNF, IL1, and IL6 known to influence hepatocyte
proliferation, alongside cell cycle genes. The analysis also revealed
selective enrichment of genes associated with portal, as opposed to
centrilobular regions, as seen in hepatic regeneration. Combined with
earlier data from the mouse, this study supports the existence of a
CSF1-dependent feedback loop, linking macrophages of the liver with
bone marrow and blood monocytes, to mediate homeostatic control of
the size of the liver. The results also provide evidence of safety and
efficacy for possible clinical applications of CSF1-Fc.
hepatosplenomegaly; CD163; macrophages; hepatostat; M-CSF
NEW & NOTEWORTHY
This study is based on extensive studies in the mouse of the role
of CSF1 in monocyte-macrophage production and differentia-
tion and the function of macrophages in the control of hepa-
tocyte proliferation. We use a novel form of CSF1, an Fc fusion
protein, to demonstrate that the findings in mice can be ex-
tended to large animals. We discuss the possible role for CSF1
in homeostatic control of the size of the liver.
MACROPHAGE COLONY-STIMULATING FACTOR (CSF1) is an essential
growth and differentiation factor for cells of the macrophage
lineage (23). Subsequent to the original isolation of human
CSF1 cDNA in the 1980s and demonstration that injection of
the recombinant CSF1 protein can expand macrophage popu-
lations in mice (24), there were a number of clinical trials of
applications in cancer and other indications (23). The interest
in CSF1 as a therapeutic agent has been reinvigorated by
evidence of the requirement for macrophages in tissue regen-
eration in multiple organs (7) and the finding that macrophages
generated in response to CSF1 have trophic roles (9, 43). CSF1
treatment has been shown to promote regeneration and repair
in injury models in the kidney (1), brain (5, 37), and bone (6).
The pleiotropic impacts of CSF1 mutations in mice (12)
suggest that repair in most tissues is reliant on macrophages
that depend on this growth factor.
Applications of CSF1 therapy were constrained by the very
short half-life of the 150-amino acid active form of CSF1. We
developed a bioactive protein with a longer half-life in the
circulation. We fused pig CSF1, which is equally active in all
mammalian species tested (20), with the Fc region of pig
IgG1a (CSF1-Fc) (21). The expected increase in half-life was
confirmed, and CSF1-Fc administration to mice produced sub-
stantial increases in circulating monocyte and tissue macro-
phage numbers, at much lower doses than the native protein.
An unexpected effect of the treatment was a substantial in-
crease in the size of the liver, associated with extensive
hepatocyte proliferation (21). This observation was consistent
with previous data implicating CSF1-dependent macrophages in
hepatic regeneration. Acute liver failure in human patients, for
example due to paracetamol toxicity, is associated with the loss of
clearance functions that protect the body against the contents of
the portal blood. Circulating CSF1 levels in human patients upon
admission to hospital with paracetamol poisoning were found to
be predictive of subsequent prognosis (46). Administration of
CSF1-Fc in mouse models produced both accelerated regenera-
tion of the liver and, perhaps more importantly, very rapid resto-
ration of clearance functions (21, 44, 46).
Pigs have been used increasingly as models of human
disease (17). The gene expression profiles of stimulated mouse
and human macrophages differ greatly, and those of pig mac-
rophages are much more human-like (29). Aside from the
possible applications as human disease models, pigs are a
major livestock species. Early weaning in pigs, when the
mucosal barrier and innate immune systems are immature, is
associated with susceptibility to a very wide range of mucosal
and systemic bacterial and viral infections that produce signif-
icant losses (3). The results obtained in mice cannot necessarily
be extrapolated to large animals, including humans, in which
the profiles of macrophage activation by both CSF1 and mi-
crobial stimuli are very different (29). Our results confirm that,
as in the mouse, CSF1-Fc can drive hepatocyte proliferation
and modulate the size of the liver in a large animal model. The
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data support applications of CSF1-Fc in liver regeneration and
provide further evidence for the role of CSF1 in monocyte/
macrophage maturation. In combination with earlier data, they
reinforce the conclusion that circulating CSF1 is a central
contributor to the homeostatic control of the size of the liver.
MATERIALS AND METHODS
Animals. Approval was obtained from Protocols and Ethics Com-
mittees of Roslin Institute or Agri-Food and Biosciences Institute
(AFBI) for the trials. The experiments were carried out under the
authority of a UK Home Office Project License, under the regulations
of Animals (scientific procedures) Act 1986. CSF1-Fc was made as
previously described (21) and provided by Zoetis.
Large White pigs 8.5 wk of age from one litter were used. Four
days prior to the first injection each pig was weighed and had blood
collected into an EDTA tube. Pigs were injected subcutaneously once a
day for a total of 3 days with the appropriate volume of CSF1-Fc (0.75
mg/kg; n 6) or PBS vehicle (n 5). PBS injection was used to control
for the possible impact of stress and restraint associated with treatment. In
experiments on weaners, Large White  Landrace pigs 4 wk of age
from three litters were used. Six days prior to the first injection each pig
was weighed and an estimated weight was extrapolated for each for the
first injection day. Pigs were injected intramuscularly once a day for 2
days with the appropriate volume of CSF1-Fc (0.75 mg/kg; n  12) or
PBS (n  12). On the second injection day the pigs were weaned. All
pigs were sedated with ketamine and azaperone before being euthanized
by captive bolt. Neither subcutaneous nor intramuscular injection pro-
duced any side effects.
Isolation of PBMC and BMC. Blood was collected into blood
collection bags containing acid citrate dextrose (ACD) (Sarstedt) or into
beakers containing ACD (Sigma). The buffy coat was layered onto
Lymphoprep (Axis-Shield) and centrifuged for 25 min at 1,200 g with no
brake. Peripheral blood mononuclear cells (PBMC) were retrieved and
red cells were removed with cell lysis buffer (BioLegend). Pig bone
marrow cells (BMC) were obtained by flushing the bone marrow from
ribs with RPMI/5 mM EDTA followed by removal of red cells with
cell lysis buffer. All isolated cells were suspended in PBS prior to
counting and cryopreservation.
Flow cytometry analysis. Cells were washed, pelleted, resuspended
in blocking buffer (PBS/2% heat inactivated FCS), transferred to a
96-well plate (V-bottom), and incubated on ice for 15–20 min. The
plate was centrifuged for 4 min at 400 g followed by removal of
supernatant. Cells were resuspended in 100 l of PBS containing the
appropriate antibody or isotype control (Table 1). Samples were
incubated at 4°C in the dark for 30 min before being washed two times
with 200 l PBS. Cells were resuspended in 600 l PBS with 0.1%
SYTOX blue (Invitrogen) immediately prior to analysis using a BD
Fortessa LSR flow cytometer (Becton Dickinson). Analysis was
performed using FlowJo software (FlowJo).
Complete blood count analysis. An aliquot of blood from ACD
blood collection bags was analyzed for complete blood cell counts.
Total white blood cell (WBC) was measured on the Siemens Advia
2120 analyzer. WBC differential counts were performed by making a
blood smear counterstained with Giemsa stain prior to cells of each
cell type being counted. The absolute value for each WBC type was
determined by using the total WBC and % leukocytes. Manual
platelets counts were carried out using a hemocytometer slide (by the
R(D)SVS Clinical Pathology Laboratory, University of Edinburgh).
Plasma analysis. Plasma was analyzed by R(D)SVS Clinical Pa-
thology Laboratory for cortisol (performed on Siemens Immulite
analyzer) as well as a large animal liver damage profile (performed on
the IL650 analyzer from Instrumentation Laboratories).
Tissue processing. Tissues were dissected, weighed (liver, spleen,
and kidney), and placed in 10% neutral buffered formalin or RNAlater
(Ambion). For histology, tissues were processed overnight using an
Excelsior tissue processor (Thermo Fisher Scientific). Sections were
embedded in paraffin wax prior to 4-m sections cut and mounted
onto slides (Superfrost Plus, Thermo Fisher Scientific). Slides were
dried overnight at 37°C before 60°C for 25 min. Sections were stained
with H&E or immunohistochemistry was performed by R(D)SVS
pathology department.
Immunohistochemistry for CD163. Antigen retrieval was performed
with proteinase K (Dako S302030) for 10 min. Nonspecific protein
binding was blocked using 2.5% goat serum (Vector Laboratories) for 20
min. Endogenous peroxidase activity was blocked using Dako REAL
peroxidase blocker (Dako S202386) for 10 min. Sections were incubated
for 60 min using mouse anti-pig CD163 (Serotec MCA2311GA) diluted
1/30. Visualization using secondary reagent Dako Envision mouse HRP
(Dako K4007) for 40 min followed by DAB (Newmarket Scientific
Monosan Dab substrate kit cat. no. MON-APP177) for 10 min and DAB
enhancer for 3 min (Newmarket Scientific DAB concentrate cat. no.
CO7-25) was performed by the R(D)SVS pathology department. The
staining was analyzed using Image J (Fiji).
Immunohistochemistry for Ki67 and PCNA. Antigen retrieval was
performed by boiling in 10 mM sodium citrate buffer. Nonspecific
protein binding was blocked using 2.5% goat serum (Vector Labora-
tories) for 20 min. Endogenous peroxidase activity was blocked using
Dako REAL peroxidase blocker (Dako S202386) for 10 min. Sections
were incubated for 60 min using rabbit anti-human Ki67 (AbCam
AB15580) diluted 1/10,000. Visualization was performed with sec-
ondary reagent ImmPRESS HRP anti-rabbit IgG (Peroxidase Poly-
mer; VectorMP-7401) for 30 min followed by DAB (Newmarket
Scientific Monosan Dab substrate kit cat. no. MON-APP177) for 10
min and DAB enhancer for 3 min (Newmarket Scientific DAB
concentrate cat. no. CO7-25).
Statistical analysis. Data were analyzed by t-tests. Results are
presented as treatment group means  SE. All analyses were per-
formed using GraphPad Prism 5.0 (GraphPad Software). A P value 
0.05 was considered statistically significant.
Microarray. Total RNA was prepared from liver samples using
TRIzol, prepared for hybridization using the Ambion WT Expression
Kit (Life Technologies), following the manufacturer’s instructions,
except for the input amount of RNA (500 ng input instead of 100 ng)
and hybridized in a random order to the Affymetrix Porcine Gene 1.1
ST array (performed by Edinburgh Genomics, University of Edinburgh).
Statistical analysis of the array data utilized Partek Genomic Suite
(Partek). For network analysis, the normalized array data were uploaded
to the software Biolayout Express3D (http://www.biolayout.org/) as de-
scribed previously (18, 30). The data from the microarray are available at
Gene Expression Omnibus NCBI (http://www.ncbi.nlm.nih.gov/geo/)
accession code GSE78837.
Table 1. Antibodies used in flow cytometry
Antigen Conjugate Isotype Supplier Dilution Isotype Control
CD16 RPE IgG1 AbD Serotec,
MCA1971PE
1:200 AbD Serotec,
MCA928PE
CD14 FITC IgG2b AbD Serotec,
MCA1218F
1:50 AbD Serotec,
MCA691F
CD163 RPE IgG1 AbD Serotec,
MCA2311PE
1:100 AbD Serotec,
MCA928PE
CD172a RPE IgG1 Southern Biotech,
4525-09
1:400 AbD Serotec,
MCA928PE
CD169 FITC IgG1 AbD Serotec,
MCA2316F
1:100 AbD Serotec,
MCA928F
CD117 AF488 IgG1 AbD Serotec,
MCA2598A48
1:10 Biolegend,
400109
CD3 FITC IgG1 AbD Serotec,
MCA5951F
1:100 AbD Serotec,
MCA928F
Antigen Conjugate Isotype Supplier Concentration Secondary Antibody
CSF1R Purified IgG2a Produced
in-house
5 g/ml Biolegend, 405308,
1:400 dilution
Summary information for all monoclonal antibodies used for flow cytometry
staining, including dilution, manufacturer, and relevant isotype control.
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RESULTS
CSF1-Fc expands macrophage populations in blood and
organs. We first examined 8-wk-old pigs of both sexes from
the same litter, with control and treated groups weight matched
in pairs. Based on mouse data (21) we used a dose of 0.75
mg/kg for three daily treatments followed by cull 24 h after
final injection. In previous studies, we have compared CSF1-Fc
with the native, non-Fc conjugate, form of CSF1 as a control
protein. Native CSF1 has a much shorter half-life and at the
same dose had no effect on monocyte-macrophage numbers
(21). We have not compared CSF1-Fc directly with an irrele-
vant fusion protein, or with an isotype control for the Fc
component. However, an equivalent dose of IgG1 (10–20 mg
depending on the size of the pig) would have no impact on the
plasma IgG concentration (15–30 mg/ml). CSF1-Fc treatment
of macrophages in vitro did not induce proinflammatory cyto-
kines (21) and, in keeping with the lack of intrinsic proinflam-
matory activity, there was no evidence of any reaction at the
sites of injection in any treated animals. The most obvious
effect of CSF1-Fc administration was hepatosplenomegaly.
CSF1-Fc doubled the spleen/body weight ratio and increased
the liver/body weight ratio by 40% after only 4 days (Fig. 1A).
The total WBC count was significantly increased, mainly
due to lymphocytosis in addition to the expected monocy-
tosis (Fig. 1B).
CSF1-Fc accelerates the maturation of macrophage popu-
lations in peripheral blood monocytes. CSF1 has been impli-
cated in the maturation of blood monocytes in both mice and
humans, driving the formation of the nonclassical (CD14low,
CD16high) subset in humans (Ly6Clow in mice) (31, 33). Pig
blood monocytes can also be separated into subsets based on
expression of surface markers, although the distinctions are not
as clear as in other species (16). Expression of various markers
by peripheral blood monocytes was assessed by flow cytometry
staining (Fig. 2). In addition to the increase in total WBC seen
in Fig. 1, the proportion of monocytes, detected by CD172a
(SIRPA) was increased around twofold (Fig. 2B). The propor-
tion of cells expressing CD16 was also increased (Fig. 2A). No
increase was seen in the percentage of CD3 lymphocytes
(Fig. 2C) The best-characterized monocyte maturation marker
in pigs is the haptoglobin receptor, CD163 (16), which has also
been implicated as a receptor for the major pig viral pathogen,
porcine reproductive and respiratory syndrome (PRRSV) (14),
and which varies inversely with CD14 expression. Double
staining with the two markers indicated that CSF1-Fc shifted
the profiles of both markers, favoring expansion of the
CD163 cells (Fig. 2D). The results are consistent with an
impact of CSF1-Fc to promote both monocyte production/
release and maturation.
Impact of CSF1-Fc treatment on the bone marrow. We next
investigated whether the ability of CSF1-Fc to promote mono-
cytosis was associated with expansion of progenitor pools in
the marrow (Fig. 3). Figure 3, A and B, demonstrates a
substantial increase in large CD14 monocytes, and even
greater increase in CD163 cells in the marrow of treated
animals, consistent with the pattern seen in blood. Aside from
monocyte progenitors, a key population of macrophages in
bone marrow forms the center of hemopoietic islands. In mice,
these cells express sialoadhesin (CD169, which provides a
receptor for immature erythrocytes) and are critical for suc-
cessful engraftment in bone marrow transplantation (10). As
shown in Fig. 3C, the CSF1-Fc treatment produced a substan-
tial increase in the CD169 population in pigs. The CSF1-Fc
treatment did not expand the small percentage of cells that
express CD117 (KIT), a marker of the stem cell population
(Fig. 3D), suggesting that CSF1-Fc acts primarily to promote
proliferation/expansion of committed progenitors. In bone
marrow of pig, neither CD172a nor CD16 provides a useful
marker of monocyte lineage cells, being detected on the large
majority of the cells (Fig. 4, A and B) and only marginally
increased by CSF1-Fc. We also examined the expression of the
CSF1R (CD115) using either a recently described monoclonal
antibody (39) or labeled CSF1-Fc. There was some evidence of
expansion of the positive cell populations in each case, but the
levels of labeling were very low (Fig. 4, C and D). We suggest
that the receptor may be downregulated by CSF1-Fc.
Fig. 1. Effect of CSF1-Fc on organ weights and white blood cell (WBC)
counts. Pigs (8-wk-old males and females) were injected with PBS or 0.75
mg/kg CSF1-Fc for 3 days prior to euthanasia on day 4. Blood was collected
into EDTA tubes postmortem and complete blood count assessment was
performed. Graphs show means  SE. **P  0.01, ***P  0.001, ****P 
0.0001 by t-test; n 5–6 pigs per treatment. A: liver weight/body weight ratio,
spleen weight/body weight ratio, and kidney weight/body weight ratio. B: total
WBC count, lymphocyte number, neutrophil number, monocyte number, and
platelet number.
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Origin of the increase in liver and spleen weight. CSF1-Fc
treatment caused a substantial increase in macrophage numbers
in both organs, detectable by immunolocalization of CD163. In
immunostained sections of liver CSF1-Fc treatment increased
CD163 area (quantified with ImageJ) from an average of less
than 0.5% to an average of over 9% (Fig. 5A). In spleen
CSF1-Fc treatment had an even greater effect, causing an
increase of CD163 area from an average from 1% to 16%
(Fig. 5B). As in mice (21), in the spleen the majority of the
increase in size could be attributed to increased red pulp
macrophages and also to expansion of the marginal zones.
By contrast, the increase in the area apparently occupied by
macrophages is not sufficient to explain the substantial increase
in the size of the liver. Sections of liver were stained for the
Fig. 2. Effect of CSF1-Fc on PBMCs. Pigs (8-wk-old males and females) were injected with PBS or 0.75 mg/kg CSF1-Fc for 3 days prior to euthanasia on day
4. Blood was collected as described in MATERIALS AND METHODS. PBMCs were analyzed via flow cytometry for expression of CD16 (A), CD172a (B), CD3 gated
on the lymphocyte population exclusively (C), or CD163/CD14 (D) with exclusion of dead cells using SYTOX blue. Representative flow cytometry plots are
shown. Graphs show means  SE. **P  0.01, ***P  0.001 by t-test; n  4–5 pigs per treatment.
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Fig. 3. Effect of CSF1-Fc on bone marrow (BM) cells. Pigs (8-wk-old males and females) were injected with PBS or 0.75 mg/kg CSF1-Fc for 3 days prior to
euthanasia on day 4. BM from ribs was collected as described in MATERIALS AND METHODS. BM cells were analyzed via flow cytometry for expression of CD14
(A), CD163 (B), CD169 (C), or cKit (D) with exclusion of dead cells using SYTOX blue. Representative flow cytometry plots are shown. Graphs show means  SE.
**P  0.01, ****P  0.0001 by t-test; n  4–5 pigs per treatment.
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Fig. 4. Further effect of CSF1-Fc on BM cells. Pigs (8-wk-old males and females) were injected with PBS or 0.75 mg/kg CSF1-Fc for 3 days prior to euthanasia
on day 4. BM from ribs was collected as described in MATERIALS AND METHODS. BM cells were analyzed via flow cytometry for expression of CD16 (A), CD172a
(B), CSF1 (C), or CSF1R (D) with exclusion of dead cells using SYTOX blue. Representative flow cytometry plots are shown. Graphs show the mean percentage
positive cells  SE, or the median fluorescent intensity. **P  0.01, ***P  0.001, ****P  0.0001 by t-test; n  4–5 pigs per treatment.
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proliferative cell marker Ki67. Figure 6 shows images of the
liver from two control and two CSF1-Fc-treated pigs. The pigs
are relatively young, and still growing, and accordingly there is
significant ongoing proliferation evident from Ki67 staining.
The vast majority of Ki67 nuclei in both control and CSF-1-
Fc-treated pig livers were large and round, consistent with
identity as hepatocytes. Macrophage nuclei are more difficult
to visualize in histological sections, because the cells and
nuclei are much smaller and ramified in the sinusoids. Very
occasional smaller Ki67 nuclei visible in the sinusoids sug-
gested that some infiltrating monocyte-macrophages were also
proliferative, as shown directly in the mouse system (46). The
images in Fig. 6 also show an obvious increase in cellularity in
response to CSF1-Fc. We counted the total nuclei and the
proportion stained with anti-Ki67 in representative large fields
from each animal. As shown in Fig. 6, CSF1-Fc treatment
almost doubled the total number of nuclei in each field and
produced a threefold increase in the percentage of those nuclei
stained with anti-Ki67. Essentially the same findings were
made with staining for proliferating cell nuclear antigen
(PCNA) (not shown). The sections in Fig. 6 show no evidence
of pathology in the liver; notably, there are no pyknotic nuclei
and granulocytes are absent. Granulocyte infiltration is the
hallmark of tissue injury, including injury to the liver (27).
Changes in the liver might occur secondary to alterations in
the gut. CSF1 has been attributed indirect functions in control
of proliferation and differentiation of gastrointestinal epithe-
lium (26, 45). Treatment with CSF1-Fc in pigs produced a
small but significant increase in the mean villus length of the
mid jejunum but had no detectable effect in the ileum, cecal
base, or ascending colon (Fig. 7). There was also no significant
change in goblet cell number.
Effect of CSF1-Fc on liver function. A panel of biochemical
tests to measure serum enzymes, bile acid, bilirubin, and
protein concentrations was performed to assess hepatic func-
tion. The only change was a small increase in bile acids and
bilirubin in serum from CSF1-Fc-treated pigs (Fig. 8), only
marginally outside the normal range (50). Since standard
enzymic indicators of liver injury (alkaline phosphatase, ala-
nine aminotransferase, 	-glutamyl transpeptidase) were un-
changed, the increase in bile acids probably reflects the in-
creased size of the liver. To examine the impact of CSF1-Fc on
liver function in more detail, we profiled the transcriptome.
The expression results were filtered to remove genes detected
below an arbitrary relative intensity threshold and also genes
that did not differ by more than 1.5-fold between the highest
and lowest value in the nine samples. The second criterion
removed around 30% of probes on the microarray, including
many hepatocyte-specific gene products. Figure 9C shows that
the relative abundance of representative examples of these
known hepatocyte gene products, albumin (ALB), CD14,
FETUIN, and transferrin (TF), within the total liver RNA pool
was unchanged in response to CSF1-Fc. In other words, the
infiltration of the liver by macrophages was insufficient to
dilute the contribution of hepatocyte mRNA to the total mRNA
pool. That finding is consistent with the histological observa-
tion above, that even in the CSF1-Fc-stimulated state the
infiltrating macrophages appear to make up no more than 10%
of the total area of the liver. Hence, the 40% increase in total
liver weight can be attributed primarily to an increase in
Fig. 5. Effect of CSF1-Fc on tissue macrophages. Pigs (8-wk-old males and females) were injected with PBS or 0.75 mg/kg CSF1-Fc for 3 days prior to
euthanasia on day 4. Formalin fixed liver (A) and spleen (B) tissue was prepared and stained for CD163. Representative images are shown. Scale bar  20 M.
Using ImageJ software the total CD163 area was calculated from 2 representative images per pig per organ. Graphs show means  SE. *P  0.05, **P 
0.01 by t-test; n  4–5 pigs per treatment.
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hepatocytes, consistent with the extensive proliferation and
increased cellularity shown in Fig. 6.
We clustered the included probe sets based on expression
pattern and displayed them using Biolayout Express3D. The
advantage of using the clustering approach is that genes that
might appear regulated, but in only a subset of animals,
appeared in separate smaller clusters. These may reflect the
interanimal variation in macrophage-inducible gene expression
that we documented previously in a study of pig breeds (30).
The gene lists of specific clusters are provided in Supplemental
Table S1. (Supplemental Material for this article is available
online at the Journal website.) Functional annotations of the
two large clusters were tested using DAVID (Supplemental
Table S2). Cluster 1, the set of genes elevated in all CSF1-Fc-
treated pigs, was clearly enriched for genes involved in the cell
cycle and innate immunity, whereas cluster 2, the set that was
reduced in the CSF1-Fc-treated pigs, was enriched in genes
involved in metabolism. Importantly, there is no evidence
among the induced genes of expression of apoptosis-associated
genes, no induction of acute phase genes, and no appearance of
classical granulocyte marker genes such as S100A8/S100A9 or
MPO. Figure 9 shows the expression profiles of a number of
genes that highlight the biological processes involved. Cluster
1 (Fig. 9A) includes many genes that were shown previously
(18) to be restricted to macrophages, such as the transcription
factor SPI1; surface markers SIRPA, EMR1, and ITGAM;
known CSF1-inducible genes PLAU, MMP9, CHI3L1, and
C1Q; endocytic receptors MARCO, MSR1, and FCGR1A; and
pattern recognition receptors TLR1, 2, 4, 6, 7, 8, and 9. On
average, the relative contribution of cluster 1, macrophage-
specific genes, to the liver total RNA increased by three- to
fivefold in response to CSF1-Fc, again consistent with the
Fig. 6. Effect of CSF1-Fc on liver prolifer-
ation. Pigs (8-wk-old males and females)
were injected with PBS or 0.75 mg/kg
CSF1-Fc for 3 days prior to euthanasia on
day 4. Formalin fixed liver tissue was pre-
pared and stained for Ki67 as described in
MATERIALS AND METHODS. Top: representa-
tive fields from 2 separate control (PBS, left)
or CSF1-Fc-treated (right) pigs. Individual
Ki67 and Ki67
 nuclei in representative
fields from each animal were counted as
shown at bottom. **P  0.01, ***P 
0.001; NS, not significant.
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histological evidence of increased macrophage content shown
in Fig. 5. In mice, the recruited monocytes express the chemo-
kine receptor CCR2 and apparently respond to CCL2 (49). By
contrast, CCR1 was enriched in the liver mRNA of treated
pigs, alongside three of its known ligands, CCL8, CCL14, and
CCL3L1. As previously observed in mice (46), monocytes
recruited to the treated livers apparently responded to proin-
flammatory signals, since cluster 1 contained numerous known
LPS-inducible genes (29) such as inflammatory cytokines
TNF, IL1A, and IL1B; interferon targets IDO1; multiple type 1
Fig. 7. Effect of CSF1-Fc on the gut. Pigs (8-wk-old males and
females) were injected with PBS or 0.75 mg/kg CSF1-Fc for 3
days prior to euthanasia on day 4. Formalin fixed sections of gut
tissue were prepared and stained for periodic acid-Schiff to
show the goblet cells. Representative images are shown. Graphs
show means  SE. ***P  0.001 by t-test; n  4–5 pigs per
treatment. A: small intestine: mid jejunum and mid ileum. Mean
villus length (m) was measured from 112–120 villi per tissue
per group. Mean crypt length (m) was measured from 100
crypts per tissue per group. B: large intestine: ascending colon
and cecal base. Mean crypt length (m) was measured from
50–80 crypts per tissue per group.
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interferon targets IRF1, IRF5, IFITM2, and IFIT3; TGFB1;
and costimulators of T cell activation CD40, CD80, and CD86.
Cluster 1 also contains numerous cell cycle-associated genes,
including PCNA; the key transcription factors FOXM1, E2F4,
E2F7, and E2F8; and several cyclin genes CCNA2, CCNA3,
CCNB2, CCNB3, CCND2, and CCND3. The increased expres-
sion of enzymes of glycolysis HK1, HK2, HK3 PFKP, PGK1,
PGD, PKM, GPI, GAPDH, and LDHA also reflects the require-
ment for aerobic glycolysis in proliferating cells (25).
Cluster 2 (Fig. 9B), the set of genes reduced in the CSF1-
Fc-treated pigs, most likely reflects the functional zonation of
the liver between periportal and perivenous regions of liver
lobules (8, 19, 48) and the selective proliferation of cells
derived from portal progenitors that has been observed in
regenerating liver (15, 34, 36). It includes genes involved in
xenobiotic metabolism and detoxification, notably P450 family
(e.g., CYP1A1, CYP2E1), glutathione S-transferases (e.g.,
GSTAA2) and aldo-ketoreductases (e.g., AKR1C1), and the
gluconeogenic enzyme PCK2, that are known to be enriched in
perivenous locations. The cluster contains the gene for the
regulator of hepatocyte stem cells, SOX9 (2), indicating that
these cells are not expanded in the CSF1-Fc-treated livers.
Unexpected members of this cluster are genes for the growth
hormone receptor (GHR) and the target, IGF1, and both estro-
gen (ESR1) and androgen (AR) receptors. Also unexpected is
the inclusion of the receptor for hepatocyte growth factor,
MET, which is implicated in regeneration (36), but this might
reflect autoregulation in response to its ligand (52).
CSF1-Fc treatment in weaning pigs. Although models of
acute liver failure in pigs have been described (32, 41), and
may be one path to clinical development of CSF1-Fc as a
treatment, it is challenging to perform sufficient replicates to
test a clinical intervention. We therefore considered an alter-
native in production pigs. Commercial pigs are normally
weaned at 4 wk, when the gut is immature. Diarrhea and
disseminated infections with organisms such as Escherichia
coli and Streptococcus suis are relatively common (38). In this
respect, the pig has been studied as a model of early-life stress
(42). The biology of early weaning in pigs may also be relevant
to intestinal failure-associated liver disease in neonates and
children (40).
Weaner pigs were treated with a higher dose of 1.0 mg/kg
CSF1-Fc for two daily injections, immediately prior to wean-
ing and on the day of weaning followed by euthanasia 24 h
following the final injection. At this early time point, there was
already a significant increase in the spleen/body weight ratio
and a trend toward increased liver/body weight ratio (Fig.
10A). The number of CD163 cells was more than tripled in
the bone marrow, from 10% to over 30% (Fig. 10B), and
increased numbers of CD163 macrophages were confirmed
by immunostaining in liver and spleen (Fig. 10C). At this time
point, there was not a significant monocytosis, indicating that
both marrow expansion and tissue macrophage proliferation
precede monocyte expansion and are likely direct effects of
CSF1-Fc.
We repeated the treatment in a larger cohort of weaned pigs.
This study was conducted in a high health status research unit,
which reflected commercial practice. We explicitly removed
zinc from the feed, which is usually added to reduce weaning-
associated infections. Given the production of inflammatory
cytokines and reduction in IGF-1 in the liver of treated pigs, we
measured weight gain daily in all animals. CSF1-Fc (0.75
mg/kg) was administered to pigs for two daily intramuscular
injections on the day before and the day of weaning, and pigs
were killed 5 days after the second injection. Although some
pigs showed evidence of mild postweaning diarrhea, all the
animals in both groups continued to gain weight rapidly (Fig.
11A). The treated pigs, like the treated mice left for longer after
the final injection, demonstrated hepatosplenomegaly (Fig.
11B), and the increased numbers of CD163 macrophages in
the liver remained evident after 5 days (Fig. 11C).
DISCUSSION
In this study we have extended previous studies in mice (21)
to examine the impact of a sustained increase in CSF1 activity
on monocyte-macrophage homeostasis. All of the impacts we
have observed are consistent with the known biological activity
of CSF1. In mice, the same impacts on monocyte-macrophage
numbers and maturation can be generated by injection of very
much higher doses of native CSF1 (21) or injection of a much
larger native form of human CSF1 (24). The doses of native
CSF1 required are prohibitive in a large animal. Although we
cannot entirely eliminate other functional contributions of the
Fc component, the increase in circulating half-life is the most
obvious explanation for the increased efficacy compared with
native CSF1.
The nature of the so-called hepatostat, which determines that
the liver returns to a size that is strictly proportional to body
Fig. 8. Effect of CSF1-Fc on circulating markers of liver damage. Pigs
(8-wk-old males and females) were injected with PBS or 0.75 mg/kg CSF1-Fc
for 3 days prior to euthanasia on day 4. Plasma was produced from whole
blood collected in an ACD blood collection bag. Graphs show means  SE.
*P 0.05 by t-test; n 5–6 pigs per treatment. A: alkaline phosphatase (AP).
B: alanine aminotransferase (ALT), 	-glutamyl transpeptidase (GGT), and
glutamate dehydrogenase (GLDH). C: cortisol. D: albumin, globulin, and total
protein. E: bile acids, and bilirubin.
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size, has continued to be something of a mystery (34, 35).
Although there are many candidates, including growth factors
and inhibitors, extracellular matrix proteins and metabolites,
and circulating hormones that can regulate hepatic regenera-
tion, it is unclear how any of them functions as a sensor. In a
previous study, we made the striking observation that CSF1
treatment of mice (using an Fc conjugate with an increased
circulating half-life) was able to increase the size of the liver as
well as the number of Kupffer cells. This ability is quite
unique. In the present study, we have extended the finding to
the domestic pig, an animal that is considerably more human-
like in size and vascular biology. The data in Fig. 6 show that
a major impact of CSF1-Fc treatment in pigs is to increase the
number of hepatocytes through extensive proliferation, so that
the total cellularity of the liver is increased even more than the
increase in total liver weight. Hepatocyte proliferation, as
opposed to hypertrophy, is also a feature of liver regeneration
in response to partial hepatectomy (34–36). We have made the
reciprocal observation in mice; namely, that prolonged deple-
tion of Kupffer cells with anti-CSF1R treatment leads to a
reduction in the size of the liver (45). Others have shown that
liver regeneration is greatly impaired in CSF1-deficient or
anti-CSF1R-treated mice (46) and in mice depleted of blood
monocytes (15) and have promoted liver repair by infusing
CSF1-stimulated macrophages into the portal vein (47). The
impact of CSF1-Fc on hepatic growth in mice was dependent
on monocyte recruitment, as evident from the impact of knock-
out of CCR2 (46). The role of monocyte-macrophage products,
including the inflammatory cytokines TNF, IL1, and IL6, in
hepatocyte proliferation has been well recognized (22, 46).
CSF1-Fc action in mice was partly dependent on IL6 (46),
which was also induced in all of the CSF1-Fc-treated pigs. The
effect of CSF1-Fc treatment demonstrates that CSF1-depen-
dent monocyte recruitment is both necessary and sufficient to
drive hepatic proliferation and can drive it beyond the homeo-
static limits even in a large animal.
The effect of CSF1 treatment supports other evidence of the
existence of a homeostatic feedback loop. Macrophages, nota-
bly those of the liver (4) and blood monocytes (51), together
regulate the level of circulating CSF1 via receptor-mediated
endocytosis. This mechanism is evident from the massive
increase in circulating CSF1 seen in animals treated with
anti-CSF1R (33), and the importance of the liver is evident
in patients following partial resection (46). The CSF1-Fc
Fig. 9. Effect of CSF1-Fc on gene expression in the liver. Pigs (8-wk-old males and females) were injected with PBS or 0.75 mg/kg CSF1-Fc for 3 days prior
to euthanasia on day 4. Liver tissue was collected in RNAlater and RNA was prepared and submitted for microarray analysis. A: expression profiles of a number
of genes from cluster 1: upregulated genes in CSF1-Fc-treated pigs and a table of the top 12 enrichment clusters with representative terms. B: expression profiles
of a number of genes from cluster 2: downregulated genes in CSF1-Fc-treated pigs and a table of the top 12 enrichment clusters with representative terms.
C: expression profiles of a number of genes that were unregulated.
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treatment reveals that elevated CSF1 can provoke expansion
of the committed monocyte pool in the marrow (Fig. 3),
maturation of the monocytes toward a resident phenotype
(Fig. 2), and infiltration of the liver (Fig. 5). Hence, the
physiological hepatostat (34 –36) may actually be a “mac-
rostat.” Of course, the increased macrophage numbers in the
liver elicited by CSF1 produce secondary impacts, not only
removing potential toxins from the portal blood, but altering
the balance of metabolism in the liver between portal and
venous-associated functions. Interestingly, resident Kupffer
cells are selectively located toward the portal vein in mouse
liver lobules (13), which might also serve to localize mac-
rophage-derived hepatocyte proliferative signals.
The expression profiling of the livers of the CSF1-Fc-treated
pigs (Fig. 9) closely parallels results obtained previously in the
mouse system (21). The newly recruited monocytes clearly
respond to TLR-mediated and other signals to express the large
majority of transcripts seen when CSF1-stimulated bone mar-
Fig. 10. Effect of a short course of CSF1-Fc in weaning pigs. Pigs (4-wk-old males and females) were injected with PBS or 1 mg/kg CSF1-Fc for 2 days prior
to euthanasia on day 3. Graphs show means  SE. *P  0.05, **P  0.01, ***P  0.001 by t-test; n  5 pigs per treatment. A: blood was collected into EDTA
tubes postmortem and complete blood count assessment was performed. Graphs show liver weight/body weight ratio, spleen weight/body weight ratio, and
monocyte number. B: BM from ribs was collected as described in MATERIALS AND METHODS. BM cells were analyzed via flow cytometry for expression of CD163
with exclusion of dead cells using SYTOX blue. Representative flow cytometry plots are shown. C: formalin-fixed liver and spleen tissue was prepared and
stained for CD163. Representative images are shown.
Fig. 11. Long-lasting effect of CSF1-Fc in
weaning pigs. Pigs (4-wk-old males and fe-
males) were injected with PBS or 0.75 mg/kg
CSF1-Fc for 2 days prior to euthanasia 5
days after the final injection; n  12 pigs per
treatment. A: body weight was recorded at
each of the time points shown and total body
weight change over the duration of the ex-
periment was graphed for PBS treated pigs
(black) and CSF1-Fc-treated pigs (red).
B: bar graphs show means  SE. ***P 
0.001, ****P  0.0001 by t-test. Graphs
show liver weight/body weight ratio, spleen
weight/body weight ratio, and kidney
weight/body weight ratio. C: formalin-fixed
liver tissue was prepared and stained for
CD163. Representative images are shown.
Scale bar  10 M.
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row-derived macrophages respond to LPS (29). However,
classical neutrophil chemoattractants such as IL8 were not
detected; we found no evidence of neutrophil infiltration, no
induction of classical acute phase response or apoptosis genes,
and no evidence of damage to liver cells. Furthermore, the pigs
showed no adverse impacts, and in weaners the treatment did
not impair their rapid growth (Fig. 11). This is consistent with
earlier data, in which recombinant CSF1 has previously been
administered in Phase 1 clinical trials by continuous infusion to
humans and was well-tolerated (11, 28), and indicates that the
Fc fusion protein does not produce any additional toxicity. The
lack of severe consequences may be attributed in part to
induction of the anti-inflammatory cytokines IL10 and TGFB1
in the liver of the treated animals. Whatever the mechanism,
the outcome suggests that CSF1-Fc specifically promotes a
proregenerative cellular response in liver, as it does in other
organs (23).
In the final set of experiments (Fig. 11), we progressed
toward the clinical application of CSF1-Fc in a pig model. The
model may also reflect a practical application in pig production
to bolster the innate immune system at weaning. We showed
that only two doses, administered intramuscularly, were suffi-
cient to produce a sustained increase in monocyte count, liver
size, and liver macrophage numbers and produced no adverse
local reaction. We propose that CSF1-Fc could provide pro-
tection against disseminated infections arising from the imma-
ture gut of early-weaned animals. Similarly, clearance func-
tions of the macrophages of the liver are crucial to prevent
sepsis in acute liver failure in humans, and CSF1-Fc rapidly
promoted clearance functions in mouse disease models (46).
The fact that administration of CSF1-Fc to pigs increased the
size of the liver and the liver macrophage population (i.e., the
clearance capacity, noting also the increased expression of
clearance receptors in the array profiles) has an obvious rele-
vance to human acute liver failure. Accordingly, we suggest
that the fundamental understanding of the central role of CSF1
in liver homeostasis can potentially translate into both human
clinical and veterinary applications.
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